ZyVersa Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $835.9K
- Price
- $0.1032
- % Change (Daily % change from the live per-ticker quote feed.)
- -6.14%
- Volume
- 2.6K
About
ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to advancing and commercializing therapies for renal (kidney) and inflammatory disorders. The company's pipeline prominently features VAR 200, a cholesterol efflux modulator aimed at addressing kidney diseases such as focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease. Furthermore, ZyVersa is advancing IC 100, a pioneering inflammasome ASC inhibitor positioned to tackle a wide array of inflammatory conditions. The company maintains its corporate headquarters in Weston, Florida.
Quick stats
Shares outstanding8.1M
Computed float6.5M
Float / shares80.6%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001859007
Websitehttps://www.zyversa.com
AI Summary
AI-generated3mo agominorneutralearnings
ZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
ZyVersa reported a Q1 2026 net loss of $1.8 million, an improvement from $2.3 million in the prior year, driven by a 78% drop in R&D spending due to a paused study and executive retirement.
The company ended the quarter with $0.3 million in cash, stating it is only sufficient to fund operations on a month-to-month basis and requires immediate additional financing.
Management plans to file an IND for IC 100 in Q4 2026 and initiate a Phase 2a trial for VAR 200 in H2 2026, contingent on securing capital.
Red flags
- Cash balance of $0.3M only sufficient to fund operations on a month-to-month basis
- R&D expenses cut 78% due to paused study and executive retirement
- Going concern risk highlighted: company will need additional financing to support continuing operations